Moxetumomab Pasudotox

The Basics

What is Moxetumomab Pasudotox?

For the treatment of adults with relapsed or refractory hairy cell leukemia who have received at least two prior systemic therapies.

Brand names for Moxetumomab Pasudotox

Lumoxiti

How Moxetumomab Pasudotox is classified

Antibodies – Monoclonal, Antineoplastic Agents

Moxetumomab Pasudotox During Pregnancy

Moxetumomab Pasudotox pregnancy category

Category N/ANote that the FDA has deprecated the use of pregnancy categories, so for some medications, this information isn’t available. We still think it’s useful to list historical info, however, given what a common proxy this has been in the past.

What we know about taking Moxetumomab Pasudotox while pregnant

N/A

Taking Moxetumomab Pasudotox While Breastfeeding

What are recommendations for lactation if you're taking Moxetumomab Pasudotox?

No information is available on the clinical use of moxetumomab pasudotox during breastfeeding. Moxetumomab pasudotox is a recombinant immunotoxin consisting of the Fv portion of the anti-CD22 antibody covalently fused to a 38 KDa fragment of Pseudomonas exotoxin-A (PE38) with potential anti-cancer activity. Because moxetumomab is a large protein molecule with a molecular weight of about 63,000, the amount in milk is likely to be very low and absorption is unlikely because it is probably destroyed in the infant’s gastrointestinal tract. Until more data become available, moxetumomab pasudotox should be used with caution during breastfeeding, especially while nursing a newborn or preterm infant.

Maternal / infant drug levels

No information is available on the clinical use of moxetumomab pasudotox during breastfeeding. Moxetumomab pasudotox is a recombinant immunotoxin consisting of the Fv portion of the anti-CD22 antibody covalently fused to a 38 KDa fragment of Pseudomonas exotoxin-A (PE38) with potential anti-cancer activity. Because moxetumomab is a large protein molecule with a molecular weight of about 63,000, the amount in milk is likely to be very low and absorption is unlikely because it is probably destroyed in the infant’s gastrointestinal tract. Until more data become available, moxetumomab pasudotox should be used with caution during breastfeeding, especially while nursing a newborn or preterm infant.

Possible effects of Moxetumomab Pasudotox on milk supply

Relevant published information was not found as of the revision date.

Possible alternatives to Moxetumomab Pasudotox

None listed